Belumosudil Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of belumosudil during breastfeeding. Because belumosudil is >98% bound to plasma proteins, amounts in milk are likely to be low. The manufacturer states that breastfeeding is not recommended during treatment with belinostat, and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Belumosudil
CAS Registry Number
911417-87-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Protein Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
